Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

β-Catenin Directs Long-Chain Fatty Acid Catabolism in the Osteoblasts of Male Mice.

Endocrinology | 2018

Wnt-initiated signaling through a frizzled receptor and the low-density lipoprotein-related receptor-5 coreceptor instructs key anabolic events during skeletal development, homeostasis, and repair. Recent studies indicate that Wnt signaling also regulates the intermediary metabolism of osteoblastic cells, inducing glucose consumption in osteoprogenitors and fatty acid utilization in mature osteoblasts. In this study, we examined the role of the canonical Wnt-signaling target, β-catenin, in the control of osteoblast metabolism. In vitro, Wnt ligands and agonists that stimulated β-catenin activation in osteoblasts enhanced fatty acid catabolism, whereas genetic ablation of β-catenin dramatically reduced oleate oxidation concomitant with reduced osteoblast maturation and increased glycolytic metabolism. Temporal ablation of β-catenin expression in osteoblasts in vivo produced the expected low-bone-mass phenotype and also led to an increase in white adipose tissue mass, dyslipidemia, and impaired insulin sensitivity. Because the expression levels of enzymatic mediators of fatty acid β-oxidation are reduced in the skeleton of β-catenin mutants, these results further confirm the role of the osteoblast in lipid metabolism and indicate that the influence of Wnt signaling on fatty acid utilization proceeds via its canonical signaling pathway.

Pubmed ID: 29077850 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Phospho-Akt (Ser473) Antibody (antibody)

RRID:AB_329825

This polyclonal targets Phospho-Akt (Ser473)

View all literature mentions

Non-phospho (Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb (antibody)

RRID:AB_11127203

This unknown targets Non-phospho (Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

View all literature mentions

Akt Antibody (antibody)

RRID:AB_329827

This polyclonal targets Akt

View all literature mentions

β-Catenin (D10A8) XP® Rabbit mAb (antibody)

RRID:AB_11127855

This monoclonal targets β-Catenin

View all literature mentions

β-Actin (8H10D10) Mouse mAb (antibody)

RRID:AB_2242334

This monoclonal targets beta-actin

View all literature mentions

Akt Antibody (antibody)

RRID:AB_329827

This polyclonal targets Akt

View all literature mentions

Phospho-Akt (Ser473) Antibody (antibody)

RRID:AB_329825

This polyclonal targets Phospho-Akt (Ser473)

View all literature mentions

β-Catenin (D10A8) XP® Rabbit mAb (antibody)

RRID:AB_11127855

This monoclonal targets β-Catenin

View all literature mentions

Non-phospho (Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb (antibody)

RRID:AB_11127203

This unknown targets Non-phospho (Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

View all literature mentions